Combination chemotherapy with docetaxel and gemcitabine in anthracycline pretreated patients with metastatic breast cancer (MBC)
| Autor: | P. C. Jong, S. J. Eelkman Rooda, Aafke H. Honkoop, C. J. Rodenburg, J. L. L. M. Coenen, J. Douma, P. H. T. H. J. Slee, R. S. Jong |
|---|---|
| Rok vydání: | 2005 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 23:728-728 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2005.23.16_suppl.728 |
| Popis: | 792 Background: There is a need for more effective 2nd line treatment options for MBC. Both docetaxel (D) and gemcitabine (G) have shown efficacy in MBC as single agents. Combination-chemotherapy, even in 2nd line, may have advantages over single agent therapy. Methods: This multicenter phase II study evaluated the efficacy and safety of D and G in patients with anthracycline pretreated MBC. Eligibility criteria included measurable disease, adequate performance status and organ- and hematological functions. Patients received i.v. G 1000 mg/m2 d1 and d8 and on day 8 immediately followed by D 75 mg/m2 every 3 weeks for 6 cycles up to a maximum of 9 cycles. Premedication for D consisted of oral dexamethason 16 mg for 3 days starting the day before D infusion. Response evaluation was performed every 3rd cycle. Results: 34/40 pts have been enrolled, 26 are evaluable for response and toxicity. Anthracycline pretreatment was given for adjuvant purposes (10/26) or for palliative purposes (16/26 patients). This la... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|